Analysis

  • Using mRNa to target tumours

    Eli Lilly recently announced it is investing $1.8bn in a project with CureVac to develop mRNA cancer vaccines. While their work is still at an early stage, research suggests that...

  • Cost control: drug pricing policies around the world

    Despite sustained scrutiny on the cost of medicines across the globe, there is little consensus on the optimal balance between protecting industry innovation and ensuring adequate access to effective treatments....

  • Pharma Technology Focus – Issue 67

    In this issue: How cancer drug resistance works, accessing funding for rare diseases, India’s attempt to redefine over the counter drugs, the biotech potential of slipper limpets, Dundee University’s influence...

  • An HIV generic for the developing world

    Under a breakthrough pricing agreement, a generic antiretroviral for HIV/AIDS containing dolutegravir will become available across the developing world for just $75 per person per year. Abi Millar looks into...

  • Breaking cancer’s drug addiction

    Cancer cells can become addicted to the drugs designed to kill them, and now a group of scientists from the Netherlands Cancer Institute has discovered the underlying mechanism. Abi Millar...

  • Could MDMA become psychiatry’s antibiotic?

    MDMA has been achieving impressive results as an experimental treatment for post-traumatic stress disorder (PTSD). Elly Earls finds out why its approval could mark the beginning of a new era...

  • Uncertain times: the Brexit effect on pharma

    With Brexit negotiations in full swing, the British and European pharma industries are gearing up for change. That Brexit will have a profound impact is not in doubt; however, the...